Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma

NCT05678998 is registered in ClinicalTrials.gov with Werewolf Therapeutics, Inc. as lead sponsor.

NCT NCT05678998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05678998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma
Lead sponsor
Werewolf Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2022
Completion date
February 5, 2025
Enrollment
25 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, non-hodgkin lymphoma